AnaptysBio to abandon eczema drug development after mid-stage trial failure
AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a ...
ETF Daily News10h
AnaptysBio (NASDAQ:ANAB) Stock Rating Lowered by HC Wainwright
AnaptysBio (NASDAQ:ANAB – Get Free Report) was downgraded by research analysts at HC Wainwright from a “buy” rating to a ...
GlobalData on MSN1d
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints
AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...
AnaptysBio price target lowered to $36 from $90 at Guggenheim
Guggenheim lowered the firm’s price target on AnaptysBio (ANAB) to $36 from $90 and keeps a Buy rating on the shares following the announcement ...
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data
AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...
AnaptysBio price target lowered to $40 from $56 at Wells Fargo
Wells Fargo analyst Derek Archila lowered the firm’s price target on AnaptysBio (ANAB) to $40 from $56 and keeps an Overweight rating on the ...
Charles Schwab Investment Management Inc. Grows Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)
Charles Schwab Investment Management Inc. raised its position in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 3.2% in the ...
FierceBiotech1d
AnaptysBio scraps atopic dermatitis asset after antibody fails to meet all endpoints in ph. 2
AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...
The Pharma Letter1d
AnaptysBio drops development of ANB032 following trial miss
San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...
Stocktwits on MSN21h
AnaptysBio Stock Under Pressure After Scrapping Eczema Drug Program: Retail Is Devastated
Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking ...
AnaptysBio to Drop Eczema Drug Candidate After Trials Miss Endpoints; Shares Fall
The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, ...
Hosted on MSN1d
HC Wainwright & Co. Downgrades AnaptysBio (ANAB)
Fintel reports that on December 11, 2024, HC Wainwright & Co. downgraded their outlook for AnaptysBio (NasdaqGS:ANAB) from Buy to Neutral. Analyst Price Forecast Suggests 257.63% Upside As of December ...